A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX as an Aid to Smoking Cessation.

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX as an Aid to Smoking Cessation.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2012

At a glance

  • Drugs Nicotine abuse vaccine (Primary)
  • Indications Smoking withdrawal
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 May 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 11 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top